Cooperative Agreement With the Kenya Medical Research Institute (KEMRI); Notice of Intent To Fund Single Eligibility Award, 13032-13033 [05-5287]
Download as PDF
<![CDATA[
13032
Federal Register / Vol. 70, No. 51 / Thursday, March 17, 2005 / Notices
FEDERAL RESERVE SYSTEM
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice of Proposals to Engage in
Permissible Nonbanking Activities or
to Acquire Companies that are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y (12
CFR Part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act. Additional information on all
bank holding companies may be
obtained from the National Information
Center website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than March 31, 2005.
A. Federal Reserve Bank of New
York (Jay Bernstein, Bank Supervision
Officer) 33 Liberty Street, New York,
New York 10045-0001:
1. HSH Nordbank, AG, Hamburg,
Germany; to engage de novo through NY
Credit Real Estate Fund, L.P., and New
York Credit Advisors LLC, a joint
venture investment, in extending credit
and servicing loans and acting as an
investment or financial advisor,
pursuant to sections 225.28(b)(1) and
(b)(6) of Regulation Y.
Board of Governors of the Federal Reserve
System, March 11, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 05–5270 Filed 3–17–05; 8:45 am]
BILLING CODE 6210–01–S
VerDate jul<14>2003
14:51 Mar 16, 2005
Jkt 205001
Agency for Healthcare Research and
Quality
Dated: March 10, 2005.
Carolyn M. Clancy,
Director.
[FR Doc. 05–5334 Filed 3–16–05; 8:45 am]
BILLING CODE 4160–90–M
Notice of Meeting
In accordance with section 10(d) of
the Federal Advisory Committee Act (5
U.S.C., Appendix 2), announcement is
made of a Health Care Policy and
Research Special Emphasis Panel (SEP)
meeting.
A Special Emphasis Panel is a group
of experts in fields related to health care
research who are invited by the Agency
for Healthcare Research and Quality
(AHRQ), and agree to be available, to
conduct on an as needed basis,
scientific reviews of applications for
AHRQ support. Individual members of
the Panel do not attend regularlyscheduled meetings and do not serve for
fixed terms or a long period of time.
Rather, they are asked to participate in
particular review meetings which
require their type of expertise.
Substantial segments of the upcoming
SEP meeting listed below will be closed
to the public in accordance with the
Federal Advisory Committee Act,
section 10(d) of 5 U.S.C., Appendix 2
and 5 U.S.C. 552b(c)(6). Grant
applications for Partnerships in
Implementing Patient Safety (RFA–HS–
05–012) are to be reviewed and
discussed at this meeting. These
discussions are likely to reveal personal
information concerning individuals
associated with the applications. This
information is exempt from mandatory
disclosure under the above-cited
statutes.
SEP Meeting on: Partnerships in
Implementing Patient Safety.
Date: April 6–8, 2005 (Open on April
6 from 2 p.m. to 3 p.m. and closed for
the remainder of the meeting).
Place: John M. Eisenberg Building,
AHRQ Conference Center, 540 Gaither
Road, Rockville, Maryland 20850.
Contact Person: Anyone wishing to
obtain a roster of members, agenda or
minutes of the nonconfidential portions
of this meeting should contact Mrs.
Bonnie Campbell, Committee
Management Officer, Office of
Extramural Research, Education and
Priority Populations, AHRQ, 540
Gaither Road, Room 2038, Rockville,
Maryland 20850, Telephone (301) 427–
1554.
Agenda items for this meeting are
subject to change as priorities dictate.
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Cooperative Agreement With the
Kenya Medical Research Institute
(KEMRI); Notice of Intent To Fund
Single Eligibility Award
A. Purpose
The Centers for Disease Control and
Prevention (CDC) announces the intent
to fund fiscal year (FY) 2005 funds for
a cooperative agreement program to:
1. To conduct field and laboratory
research and implement public health
programs on important human
infectious diseases, with an emphasis
on HIV/AIDS, malaria, emerging and
other emerging and re-emerging
infectious diseases as well as other
identifiable public health problems.
2. To provide training for students
and public health professionals in basic
and applied public health research,
public health program planning,
implementation and evaluation and
other related issues such as data
collection, financial planning and
management.
3. To strengthen the Kenya Medical
Research Institute KEMRI) institutional
capacity to conduct research, plan,
implement and evaluate public health
programs, provide surveillance, and
develop interventions as well as support
national and regional infectious disease
identification and control efforts.
4. To incorporate the results of
research into operational disease
prevention and control programs in the
Republic of Kenya and ensure sharing of
expertise and research findings with
other nations.
The Catalog of Federal Domestic
Assistance number for this program is
93.283.
B. Eligible Applicant
Assistance will be provided only to
KEMRI. No other applications are
solicited. KEMRI is the most appropriate
and qualified agency to conduct the
activities specified under this
cooperative agreement because:
1. KEMRI is the only research
organization in Kenya that possesses the
requisite scientific and technical
expertise, the infrastructure capacity
and who has conducted malaria and
E:\FR\FM\17MRN1.SGM
17MRN1
Federal Register / Vol. 70, No. 51 / Thursday, March 17, 2005 / Notices
HIV research in areas of high morbidity
(20 years for malaria and 10 years for
HIV/AIDS). These combined attributes
make them uniquely qualified as the
only organization in Kenya capable of
effectively conducting the research and
public health program activities
proposed for this cooperative
agreement.
2. A major operational unit of KEMRI
is located in an area of western Kenya
with intense and perennial malaria
transmission and where incidence and
prevalence is very high, and thus is
ideally located to evaluate approaches
to preventing and controlling these
public health problems.
3. KEMRI was established through the
Science and Technology Act of the
Republic of Kenya and has a Board of
Management appointed by the Minister
of Health which is responsible for
overseeing all research and which has a
well-developed secretariat to provide
administrative and technical support to
research services.
4. KEMRI has been collaborating with
health agencies on priority infectious
disease research for over 20 years on the
grounds of KEMRI facilities in Nairobi,
Kisumu and other locations in Kenya.
KEMRI has experienced staff,
equipment, and facilities to support the
collaboration.
C. Funding
Approximately $5,000,000 is available
in FY 2005 to fund this award. It is
expected that the award will begin on or
before August 15, 2005, and will be
made for a 12-month budget period
within a project period of up to five
years. Funding estimates may change.
D. Where To Obtain Additional
Information
For general comments or questions
about this announcement, contact:
Technical Information Management,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341–4146. Telephone: 770–488–2700.
For program issues, contact: Ron
Stoddard, Division of Parasitic Diseases,
4770 Buford Highway, Atlanta, GA
30341. Telephone: (770) 488–7707. Email: RStoddard@cdc.gov.
Dated: March 11, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 05–5287 Filed 3–16–05; 8:45 am]
BILLING CODE 4163–18–P
VerDate jul<14>2003
14:51 Mar 16, 2005
Jkt 205001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Building Comprehensive Prevention
Program Planning and Evaluation
Capacity for Rape Prevention and
Education Funded Programs
Announcement Type: New.
Funding Opportunity Number: RFA 05037.
Catalog of Federal Domestic Assistance
Number: 93.136.
Key Dates:
Letter of Intent Deadline: April 18, 2005.
Application Deadline: May 16, 2005.
I. Funding Opportunity Description
Authority: This program is authorized
under section 393B of the Public Health
Service Act (42 U.S.C. section 280b).
Purpose: The Centers for Disease
Control and Prevention (CDC)
announces the availability of a fiscal
year 2005 cooperative agreement to
build comprehensive prevention
program planning and evaluation
capacity among selected Rape
Prevention and Education (RPE) funded
sexual violence prevention programs
and to assess short-term and
intermediate capacity building
outcomes for each program. Prevention
program planning and evaluation will
be focused on the national Rape
Prevention and Education Program logic
model as well as comprehensive
primary prevention strategies. In May
2004 CDC completed an evaluability
assessment of the national RPE program.
One of the key recommendations of the
evaluability assessment is to build
capacity for prevention program
planning and evaluation among funded
recipients.
Specific purposes of this funding are
to:
1. Increase the capacity of selected
Rape Prevention and Education funded
programs to engage in comprehensive
prevention program planning for their
state Rape Prevention and Education
Program.
2. Increase the capacity of selected
Rape Prevention and Education funded
programs to develop and implement an
evaluation of their state Rape Prevention
and Education Program.
3. Increase the capacity of selected
Rape Prevention and Education funded
programs to sustain program planning
and evaluation efforts after this
cooperative agreement has ended.
4. Assess short-term and intermediate
program planning and evaluation
capacity building outcomes for each
program.
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
13033
5. Disseminate lessons learned to
assist sexual violence prevention
practitioners in programmatic decision
making and evaluation.
For the purposes of this program
announcement the following definition
applies:
Sexual Violence: Any sexual act,
attempt to obtain a sexual act, unwanted
sexual comments or advances, or acts to
traffic, or otherwise directed, against a
person’s sexuality using coercion, by
any person regardless of their
relationship to the victim, in any
setting, including but not limited to
home or work (Jewkes, R., Sen, P. and
Garcia-Moreno, C., 2002).
This program addresses the ‘‘Healthy
People 2010’’ focus area(s) of Injury and
Violence Prevention.
Measurable outcomes of the program
will be in alignment with the following
performance goal for the National
Center for Injury Prevention and Control
(NCIPC):
Increase the capacity of injury
prevention and control programs to
address the prevention of injuries and
violence.
This announcement is only for nonresearch activities supported by CDC/
ATSDR. If research is proposed, the
application will not be reviewed. For
the definition of research, please see the
CDC Web site at the following Internet
address: https://www.cdc.gov/od/ads/
opspoll1.htm.
Activities:
Awardee activities for this project are
as follows:
a. Maintain current or increased level
of program activities and staffing.
b. Convene a state prevention team
that includes agencies, organizations
and individuals who can inform the
program planning and evaluation
process.
c. Collaborate with CDC, CDC
identified consultant(s) and the state
prevention team in developing a
comprehensive prevention program and
evaluation plan for their state Rape
Prevention and Education Program.
d. Contract with an in-state evaluator
to assist the state prevention team in
comprehensive program planning and
evaluation efforts. The evaluator should
operate from an empowerment
evaluation framework to increase state
capacity regarding comprehensive
program planning and evaluation. The
evaluator is expected to attend program
planning and evaluation trainings
provided by CDC and CDC identified
consultant(s). The evaluator should be
hired, or an internal evaluator
identified, by March 2006.
e. Collaborate with CDC, the CDC
identified consultant(s), the in-state
E:\FR\FM\17MRN1.SGM
17MRN1
]]>Agencies
[Federal Register Volume 70, Number 51 (Thursday, March 17, 2005)]
[Notices]
[Pages 13032-13033]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-5287]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Cooperative Agreement With the Kenya Medical Research Institute
(KEMRI); Notice of Intent To Fund Single Eligibility Award
A. Purpose
The Centers for Disease Control and Prevention (CDC) announces the
intent to fund fiscal year (FY) 2005 funds for a cooperative agreement
program to:
1. To conduct field and laboratory research and implement public
health programs on important human infectious diseases, with an
emphasis on HIV/AIDS, malaria, emerging and other emerging and re-
emerging infectious diseases as well as other identifiable public
health problems.
2. To provide training for students and public health professionals
in basic and applied public health research, public health program
planning, implementation and evaluation and other related issues such
as data collection, financial planning and management.
3. To strengthen the Kenya Medical Research Institute KEMRI)
institutional capacity to conduct research, plan, implement and
evaluate public health programs, provide surveillance, and develop
interventions as well as support national and regional infectious
disease identification and control efforts.
4. To incorporate the results of research into operational disease
prevention and control programs in the Republic of Kenya and ensure
sharing of expertise and research findings with other nations.
The Catalog of Federal Domestic Assistance number for this program
is 93.283.
B. Eligible Applicant
Assistance will be provided only to KEMRI. No other applications
are solicited. KEMRI is the most appropriate and qualified agency to
conduct the activities specified under this cooperative agreement
because:
1. KEMRI is the only research organization in Kenya that possesses
the requisite scientific and technical expertise, the infrastructure
capacity and who has conducted malaria and
[[Page 13033]]
HIV research in areas of high morbidity (20 years for malaria and 10
years for HIV/AIDS). These combined attributes make them uniquely
qualified as the only organization in Kenya capable of effectively
conducting the research and public health program activities proposed
for this cooperative agreement.
2. A major operational unit of KEMRI is located in an area of
western Kenya with intense and perennial malaria transmission and where
incidence and prevalence is very high, and thus is ideally located to
evaluate approaches to preventing and controlling these public health
problems.
3. KEMRI was established through the Science and Technology Act of
the Republic of Kenya and has a Board of Management appointed by the
Minister of Health which is responsible for overseeing all research and
which has a well-developed secretariat to provide administrative and
technical support to research services.
4. KEMRI has been collaborating with health agencies on priority
infectious disease research for over 20 years on the grounds of KEMRI
facilities in Nairobi, Kisumu and other locations in Kenya. KEMRI has
experienced staff, equipment, and facilities to support the
collaboration.
C. Funding
Approximately $5,000,000 is available in FY 2005 to fund this
award. It is expected that the award will begin on or before August 15,
2005, and will be made for a 12-month budget period within a project
period of up to five years. Funding estimates may change.
D. Where To Obtain Additional Information
For general comments or questions about this announcement, contact:
Technical Information Management, CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA 30341-4146. Telephone: 770-488-2700.
For program issues, contact: Ron Stoddard, Division of Parasitic
Diseases, 4770 Buford Highway, Atlanta, GA 30341. Telephone: (770) 488-
7707. E-mail: RStoddard@cdc.gov.
Dated: March 11, 2005.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control
and Prevention.
[FR Doc. 05-5287 Filed 3-16-05; 8:45 am]
BILLING CODE 4163-18-P
